Share

March 01, 2022; 98 (9) Research Article

Association of β-Amyloid and Basal Forebrain With Cortical Thickness and Cognition in Alzheimer and Lewy Body Disease Spectra

Han Soo Yoo, Seun Jeon, Enrica Cavedo, MinJin Ko, Mijin Yun, Phil Hyu Lee, Young H. Sohn, Michel J. Grothe, Stefan Teipel, Harald Hampel, Alan C. Evans, Byoung Seok Ye
First published December 30, 2021, DOI: https://doi.org/10.1212/WNL.0000000000013277
Full PDF
Short Form
Citation
Permissions

Make Comment

See Comments

Downloads
137

Share

Article Information

vol. 98 no. 9 e947-e957
DOI: 
https://doi.org/10.1212/WNL.0000000000013277
PubMed: 
34969939
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Print ISSN: 
0028-3878
Online ISSN: 
1526-632X
History: 
  • Received June 17, 2021
  • Accepted in final form December 21, 2021
  • First Published December 30, 2021.

Article Versions

Copyright & Usage: 
© 2021 American Academy of Neurology

Author Disclosures

    1. Han Soo Yoo, MD*,
    2. Seun Jeon, PhD*,
    3. Enrica Cavedo, PhD,
    4. MinJin Ko, BS,
    5. Mijin Yun, MD, PhD,
    6. Phil Hyu Lee, MD, PhD,
    7. Young H. Sohn, MD, PhD,
    8. Michel J. Grothe, PhD,
    9. Stefan Teipel, MD,
    10. Harald Hampel, MD, PhD,
    11. Alan C. Evans, PhD and
    12. Byoung Seok Ye, MD, PhD
  1. Han Soo Yoo, MD*,
    2. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  2. Seun Jeon, PhD*,
    3. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  3. Enrica Cavedo, PhD,
    4. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. Since 2019 Enrica Cavedo is an employee of Qynapse, this work has been performed during her previous position at Sorbonne University.

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  4. MinJin Ko, BS,
    5. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  5. Mijin Yun, MD, PhD,
    6. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  6. Phil Hyu Lee, MD, PhD,
    7. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. National Research Foundation of Korea (NRF) funded by the Ministry of Science, ICT and Future Planning (NRF- 2019R1A2C2085462)

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  7. Young H. Sohn, MD, PhD,
    8. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. Korean Movement Disorder Society, funding for travel to conference

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  8. Michel J. Grothe, PhD,
    9. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. (1) Instituto de Salud Carlos III (ISCIII), Miguel Servet fellowship [CP19/00031], 2020-2025 (2) Instituto de Salud Carlos III (ISCIII, research grant [PI20/00613], PI, 2021-2024

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. Alzheimer Forschung Initiative e.V.

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  9. Stefan Teipel, MD,
    10. Scientific Advisory Boards:

    1. ROCHE Pharma AG, Emil-Barell-Str. 1, 79639 Grenzach- Wyhlen, Switzerland MSD Sharp & Dohme GmbH, Lindenplatz 1, 85540 Haar, Germany Biogen GmbH, Riedenburger Str. 7, 81677 München, Germany GRIFOLS Deutschland GmbH Dr. Willmar Schwabe GmbH & Co. KG

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. MSD Sharp & Dohme GmbH Quality circle for physicians in Kühlungsborn, Talk: „Dementia and Diabetes – current report“ Talk on

    Editorial Boards:

    1. Alzheimer's and Dementia, Associate Editor, 8 years DADM Senior Editor, 5 years Journal of Alzheimer's Disease, Associate Editor: 2 years

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. (1) ROCHE, Roche Pharma AG, Grenzach, Phase III trial (2) Lilly Deutschland GmbH, Observational Study (3) Böhringer-Ingelheim Pharma GmbH & Co. KG, Germany,Observational Study (4) Molecular Life Imaging, Germany, Observational Study (5) Fujifilm Toyama Chemical, Phase III trial

    Research Support, Government Entities:

    1. (1) Federal Ministry of Research (BMBF), SiNDeM, FKZ: 16SV7091, co-investigator, 2014-2015 (2) Federal Ministry of Research (BMBF), InsideDem, FKZ: V4PID011, co-investigator, 2015-2018 (3) Ministry of Economics of the State Mecklenburg Western Pomerania, SAMi, co-investigator, 2018 -2020 (4) Federal Ministry of Research (BMBF), AgeGain, FKZ: 01GQ1425B, co-investigator, 2015-2019

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  10. Harald Hampel, MD, PhD,
    11. Scientific Advisory Boards:

    1. Commercial entities: 1) Eli Lilly, 2) Avid, 3) Jung Diagnostics, 4) Cytox, 5) Oryzon, 6) Axovant, 7) Anavex, 8) GE, 9) Roche, 10) Eisai, 11) Qynapse Non-profit entities: OECD, Alzheimer Association, Alzheimer Research Foundation (Paris), Axa Research Fund

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. Commercial entities: 1) Roche, 2) Eisai

    Editorial Boards:

    1. Senior Associate Editor of Alzheimer's & Dementia Associate Editor: Journal of Alzheimer's disease, Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring’ (DADM), European Journal of Neurodegeneration, Brain Aging, Functional Neurology; Editorial Board Member: Neuroscience Imaging, Journal of Medical Psychology, World Journal of Neurology, World Journal of Pharmacology, Journal of Diagnostics, European Journal of Neurodegeneration, Journal of Diagnostic Imaging in Therapy.

    Patents:

    1. 11 patents, no royalties

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. I am an employee of Eisai Inc. in the position of Vice President, Chief Medical Officer, Neurology Business Group, since May 1, 2019.

    Consultancies:

    1. Commercial entities: 1) Eli Lilly, 2) Avid, 3) Jung Diagnostics, 4) Cytox, 5) Oryzon, 6) Axovant, 7) Anavex, 8) GE, 9) Roche, 10) Qynqpse, 11) Eisai Non-profit entities: OECD, Alzheimer Association (Paris), Axa Research Fund

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. 1) Pfizer 2) Avid - both paid to institution

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. Alzheimer Research Foundation (Paris)

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  11. Alan C. Evans, PhD and
    12. Scientific Advisory Boards:

    1. 1) Brain Canada: funding agency, non-profit

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. travel: American Academy of Neurology, Los Angeles

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. Biospective Inc. - $30,000 p.a.

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. 1) Brain Canada – Azrieli Foundation Nerodevelopmental Research Program AC Evans “Structural and functional networks in Autism Spectrum Disorder and Fragile X Syndrome” Role on project: P.I.$2,500,000 over 3 years April 1, 2014 – March 31st,2019 2) Brain Canada – Platform Support Grants (PSG) Program AC Evans et al. “CBRAIN: Canadian Brain Research And Informatics Platform” Role on project: P.I. $2,999,960 over 3 years September 1, 2014 – August 31, 2017 3) Canadian Institutes of Health Research H Chertkow et al. “Canadian Consortium on Neurodegeneration in Aging” Role on project: Data Coordinating Centre P.I. Evans component: $1,500,000 over 5 years September 1, 2014 – August 31, 2019 4) Brain Canada – Platform Support Grants (PSG) Program AC Evans et al. “A national coordinating neuroinformatics framework for autism and related conditions” Role on project: P.I. $1,552,398 over 3 years Apr 1, 2016 – Mar 31, 2019 5) Canada Foundation for Innovation: Cyberinfrastructure Program AC Evans et al. “CBRAIN: A national high-performance computing platform for brain” Role on project: PI $ 2,953,355 over 3 years Apr 1, 2016 – Mar 31, 2019 6) Canada First Research Excellence Fund (CFREF) AC Evans et al. “Healthy Brains for Healthy Lives” Role on project: Scientific Director $ 84,000,000 over 7 years Oct 1, 2016 – Sep 30, 2023 7) Brain Canada – Platform Support Grants (PSG) Program AC Evans et al. “Canadian Open Neuroscience Pllatform (CONP)” Role on project: PI $10,995,000 over 3 years Oct 1, 2017 – Sep 30, 2020 8) Fonds de recherché du Quebec: Québec-China- Cuba Brain imaging and neuroinformatics AC Evans et al. “Tri-national axis in normal and pathological cognitive aging” Role on project: PI $300,000 over 3 years Jan 1, 2018 – Dec 31, 2020

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  12. Byoung Seok Ye, MD, PhD
    13. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. (1) the Korean Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI) and Korea Dementia Research Center (KDRC), funded by the Ministry of Health & Welfare and Ministry of Science and ICT, Republic of Korea (grant number : HU20C0511020021)

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  1. From the Department of Neurology (H.S.Y., S.J., P.H.L., Y.H.S., B.S.Y.), Brain Research Institute (S.J.), Severance Biomedical Science Institute (M.J.K.), and Department of Nuclear Medicine (M.Y.), Yonsei University College of Medicine, Seoul, South Korea; Sorbonne University (E.C., H.H.), GRC N0. 21, Alzheimer Precision Medicine, AP-HP, Pitié-Salpêtrière Hospital; Qynapse (E.C.), Paris, France; German Center for Neurodegenerative Diseases (DZNE)–Rostock/Greifswald (M.J.G., S.T.), Rostock, Germany; Unidad de Trastornos del Movimiento (M.J.G.), Servicio de Neurología y Neurofisiología Clínica, Instituto de Biomedicina de Sevilla, Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla, Spain; Department of Psychosomatic Medicine (S.T.), University Medicine Rostock, Germany; and McGill Center for Integrative Neuroscience (A.C.E.), Montreal Neurological Institute, McGill University, Quebec, Canada.
  1. Correspondence
    Dr. Ye romel79{at}gmail.com
View Full Text

Article usage

Article usage: December 2021 to April 2022

AbstractFullPdfSource
Dec 202126204Highwire
Jan 20221083059Highwire
Feb 20224141621Highwire
Mar 20227935835Highwire
Apr 20222352318Highwire

Disputes & Debates: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
Advertisement

Related Articles

  • No related articles found.

Topics Discussed

Alert Me